http://www.onemedplace.com/blog/wp-content/uploads/2009/12/heart.jpg
Canadian biopharmaceutical company Resverlogix has commenced a Phase II clinical trial for RVX-208, its small molecule therapy for the treatment of atherosclerosis in patients with stable coronary...
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2010/05/hand-heart.jpg
Cameron Health has released positive clinical trial data on a unique therapy to prevent sudden cardiac arrest, a leading cause of death in the U.S.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2011/03/hypertension.jpg
Last year, Accord Biosciences was awarded a Phase II National Institutes of Health Small Business Innovation Research grant of $1.3M to develop a point-of-care diagnostic for pulmonary arterial...
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2011/11/neovasc-reducer-1_...
Results of a published prospective three-year clinical study have demonstrated that the Reducer is safe and effective at providing relief of angina symptoms in refractory angina patients.
View Article
More Pages to Explore .....
